OTCPK:CBIS

Stock Analysis Report

Executive Summary

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Cannabis Science's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CBIS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-52.0%

CBIS

-4.0%

US Pharmaceuticals

-7.6%

US Market


1 Year Return

-87.1%

CBIS

1.0%

US Pharmaceuticals

10.2%

US Market

Return vs Industry: CBIS underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: CBIS underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

CBISIndustryMarket
7 Day-52.0%-4.0%-7.6%
30 Day-62.3%-5.0%-4.5%
90 Day-80.4%1.3%-0.6%
1 Year-87.1%-87.1%3.5%1.0%12.5%10.2%
3 Year-90.1%-90.1%20.1%11.5%37.1%28.3%
5 Year-94.2%-94.2%22.9%9.4%60.8%43.2%

Price Volatility Vs. Market

How volatile is Cannabis Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cannabis Science undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cannabis Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cannabis Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CBIS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cannabis Science regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Cannabis Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannabis Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cannabis Science performed over the past 5 years?

12.6%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cannabis Science has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Cannabis Science's financial position?


In this section we usually analyse Cannabis Science's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Cannabis Science has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CBIS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Cannabis Science's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is Cannabis Science's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBIS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CBIS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBIS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBIS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBIS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Raymond Dabney (54yo)

4.9yrs

Tenure

US$418,842

Compensation

Mr. Raymond C. Dabney is a Co-Founder of Crown Baus Capital Corp. and has been its Chief Executive Officer and President since January 13, 2015. Mr. Dabney is a Co-founder of Cannabis Science, Inc. and has ...


CEO Compensation Analysis

Compensation vs Market: Raymond's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: Insufficient data to compare Raymond's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Raymond Dabney
Co-Founder4.9yrsUS$418.84kno data
Benjamin C. Tam
CFO, Secretary & Director3.1yrsUS$113.00kno data
Robert Kane
COO & Director5.9yrsUS$260.38kno data
Mario Lap
President of European Operations & Director6.8yrsUS$215.38kno data
Alfredo Dupetit-Bernardi
CEO & President of Cannabis Science GmbH4.1yrsUS$69.32kno data
Bret Bogue
Director of Horticulture and Head of Research & Development0yrsno datano data
Christopher Meenan
Executive Vice President of Product Research & Development6.9yrsno datano data

4.1yrs

Average Tenure

57yo

Average Age

Experienced Management: CBIS's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Raymond Dabney
Co-Founder4.9yrsUS$418.84kno data
Benjamin C. Tam
CFO, Secretary & Director3.1yrsUS$113.00kno data
Robert Kane
COO & Director5.9yrsUS$260.38kno data
Mario Lap
President of European Operations & Director6.8yrsUS$215.38kno data
J. August
Member of Scientific Advisory Board0yrsno datano data
Roscoe Moore
Member of Scientific Advisory Board & Member of International Government Affairs Board0yrsUS$260.00kno data
Robert Melamede
Member of Scientific Advisor Board5.3yrsUS$386.25kno data
Ritchard Fishman
Member of Scientific Advisory Board10.2yrsno datano data
Julius Garvey
President of Scientific Advisory Board1.1yrsno datano data
Jacques Walker
President of International Government Affairs Advisory Board1.1yrsno datano data

5.3yrs

Average Tenure

67yo

Average Age

Experienced Board: CBIS's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Cannabis Science, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cannabis Science, Inc.
  • Ticker: CBIS
  • Exchange: OTCPK
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$13.455m
  • Shares outstanding: 2.75b
  • Website: https://www.cannabisscience.com

Number of Employees


Location

  • Cannabis Science, Inc.
  • 19800 MacArthur Boulevard
  • Suite 300
  • Irvine
  • California
  • 92612
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBISOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2009
CXNBST (Boerse-Stuttgart)YesCommon StockDEEURMar 2009

Biography

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, benefits of medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. Further, it operates an industrial hemp research and development project. It has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug; and a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to develop and investigate the use of cannabinoids to cure various cancers, as well as with Stellenbosch University to treat chronic pelvic pain associated with pelvic inflammatory disease in women, chronic prostatitis in men, and other chronic pain associated with other indications. Cannabis Science, Inc. also has a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to investigate the use of extract from the Justicia plant to treat blood disorders. The company was formerly known as Gulf Onshore, Inc. and changed its name to Cannabis Science, Inc. in April 2009. The company was incorporated in 1996 and is based in Irvine, California. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/26 00:11
End of Day Share Price2019/10/24 00:00
Earnings2017/09/30
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.